TLR3 and pancreatitis: Waterman et al. [5] demonstrated that MSCs pretreated with the TLR3 agonist poly (I : C) exhibited enhanced anti-inflammatory properties, in our experiment, poly(I : C) pretreated ADSCs adapted an anti-inflammatory phenotype with higher levels of IL-10 and TGF-β secretion, demonstrating a strengthened capability in inhibiting inflammatory cascades in pancreatitis compared with untreated ADSCs.